BKIT - BioHemp International, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0000 (0.00%)
At close: 2:33PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close0.0100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0100 - 0.0100
52 Week Range0.0001 - 4.0000
Avg. Volume346
Market Cap24,870
Beta (5Y Monthly)-5.25
PE Ratio (TTM)N/A
EPS (TTM)-0.3170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    BioHemp International Provides Update on Current Status and its CBD Business Model

    NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – BioHemp International, Inc. (BKIT), (“Company”), a Company focused on consolidating distributors in the CBD industry, provides update on its current status, and outline of its future business model. The Company is pleased to announce it has retained two law firms to begin the process of bringing the company back to 'current' tier status with OTC Markets and the Securities and Exchange Commission (SEC). The Company is working diligently to provide all requested documentation, and is working tirelessly to retain its fully reporting status.

  • GlobeNewswire

    BioHemp International, Inc. (OTC: BKIT) Acts in Response to SEC and OTC Trading Suspension

    NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – As previously disclosed on July 26th, 2019, the Securities and Exchange Commission ("Commission") announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the "Exchange Act"), of trading in the securities (the “Trading Suspension”) of BioHemp International (“BioHemp”) (BKIT) of New York, NY at 9:30 a.m. EDT on July 26, 2019, and terminating at 11:59 p.m. on August 8th, 2019.  BKIT is currently communicating and fully cooperating with the Commission to seek the removal of the Trading Suspension and to permit a resumption of trading on the OTC Pink market. The Commission temporarily suspended trading in the securities of BioHemp because of questions about the accuracy and adequacy of information publicly disseminated concerning BioHemp, including, among other things, potentially manipulative or deceptive activity relating to the Company.

  • GlobeNewswire

    BioHemp International (OTC: BKIT) Clarifies Recent 8-K - No Material Change in Share Structure

    NEW YORK, July 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – BioHemp International, Inc. (BKIT) (the "Company”) clarifies that in the 8-K filed on July 12th, 2019, the 25 million shares issued as part of the transaction, was completed on March 9th, 2019. No additional shares have been issued, and there has not been a material change to the Company's issued and outstanding share structure which is 28,850,700 million shares outstanding reflected on the Company's OTC Markets profile, that has been verified by the Company’s transfer agent.

  • GlobeNewswire

    Daniel Blum, CEO at BioHemp International (OTC: BKIT), discusses new position, CBD opportunities, and long-term company goals with Cannabis Hemp Wire

    NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Cannabis Hemp Wire’s David Hempstein interviewed new BioHemp International (BKIT) CEO, Daniel Blum earlier this week to discuss new role, opportunities in the cannabinoid (CBD) market and both short and long term corporate goals. Mr. Blum joined BioHemp International, a Company focused on rolling up a distribution platform for CBD providers to become the leading consolidation force in the CBD industry, in June this year. Hempstein opened the interview with a discussion about the existing opportunities available in the CBD space, to which Mr. Blum commented, “When you consider how cannabis has become increasingly integrated into mainstream society, as represented by the number of states that have legalized recreational or medical markets, CBD will be on the rise for the coming years.

  • GlobeNewswire

    American Premium Water Corp. (OTC:HIPH) Announces Agreement to Allow BioHemp International (OTC:BKIT) to Private Label CBD Water and Beverages Utilizing Company’s Technology

    PLAYA VISTA, CA, July 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Premium Water Corporation (HIPH) (“the Company”) announces that it has agreed to a deal that will imminently be executed allowing BioHemp International (BKIT) to license the Company’s proprietary Hydro Nano technology to be used to manufacture water and other CBD infused beverages across BKIT’s current and future platforms. American Premium CEO, Ryan Fishoff, commented, “This is a great deal for the Company.

  • GlobeNewswire

    BioHemp International, Inc. (OTC: BKIT) Announces Deal to Private Label Water From American Premium Water Corporation (OTC: HIPH)

    NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – BioHemp International, Inc. (BKIT), (“Company”), a Company focused on consolidating the CBD industry, announces that it has entered an agreement with American Premium Water Corporation (HIPH) to white label cannabidiol (CBD) infused water utilizing HIPH’s proprietary Hydro Nano technology. The agreement provides exclusivity to the Company to utilize this technology and sell water across all its current and future platforms.

  • GlobeNewswire

    Ludlow Research Initiates Coverage on BioHemp International (BKIT) Based on CBD Distribution Business Model And Assigns A Short Term 'Speculative' Price Target Per Share of $2.50 -$3.50

    NEW YORK, July 02, 2019 -- via OTC PR WIRE -- BioHemp International, Inc. (OTC: BKIT), (“Company”) announces a research opinion on the company is now available for download..

  • CBD from Walmart to Kroger: Bigger Distribution Deals In Preparation For A Global CBD Market

    CBD from Walmart to Kroger: Bigger Distribution Deals In Preparation For A Global CBD Market

    Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - June 25, 2019) - Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot reporting on the recent rush of large scale distribution deals surrounding new CBD products. Companies featured include American Premium Water Corporation (OTC Pink: HIPH), BioHemp International, Inc. (OTC Pink: BKIT), New Age Beverages Corporation (NASDAQ: NBEV) and LinkResPet (OTC Pink: LRSV).Read the full article on Investorideas.com:https://www.investorideas.com//News/2019/cannabis/06250CBD-WalmartKroger.aspA recent ...

  • GlobeNewswire

    BioHemp International, Inc (OTC: BKIT) Appoints Ryan Fishoff as Lead Advisor to Company to Assist With CBD Distribution Consolidation Focus 

    The ‘King of CBD’ joins the Company as an advisor to help lead its rollup strategy. NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – BioHemp International, Inc. (BKIT), (“Company”) announces that it has appointed American Premium Water Corporation (HIPH) Chief Executive Officer Ryan Fishoff as Lead Advisor to the Company. Mr. Fishoff will assist Company CEO, Daniel Blum with M&A Strategy and CBD industry knowledge as the Company begins its consolidation rollup strategy.

  • GlobeNewswire

    Blake Insomnia Therapeutics, Inc Completes Name Change to BioHemp International, Inc (OTC: BKIT) and Appoints Daniel Blum as New CEO to Spearhead CBD Distribution Consolidation Focus 

    NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – The Company, previously Blake Insomnia Therapeutics Inc, confirms its successful name change to BioHemp International, Inc. (BKIT) and announces the appointment of Daniel Blum as its new Chief Executive Officer, assuming his position immediately. The market ticker will change to BKITD for the following twenty working days, reverting back to BKIT after this period. As the market begins to consolidate, the Company is poised to benefit from its first mover advantage.